Dishman Carbogen Amcis Ltd vs Glenmark Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Dishman Carbogen Amcis Ltd is ₹ 186.15 as of 05 May 15:30 . The P/E Ratio of Dishman Carbogen Amcis Ltd changed from 161 on March 2022 to 1036 on March 2025 . This represents a CAGR of 59.28% over 4 yearsThe P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 13.5 on March 2021 to 41.5 on March 2025 . This represents a CAGR of 25.18% over 5 years The Market Cap of Dishman Carbogen Amcis Ltd changed from ₹ 1708 crore on March 2021 to ₹ 3411 crore on March 2025 . This represents a CAGR of 14.83% over 5 yearsThe Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 13108 crore on March 2021 to ₹ 43458 crore on March 2025 . This represents a CAGR of 27.09% over 5 years The revenue of Dishman Carbogen Amcis Ltd for the Dec '25 is ₹ 726.46 crore as compare to the Sep '25 revenue of ₹ 660.76 crore. This represent the growth of 9.94% The revenue of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 3945 crore as compare to the Sep '25 revenue of ₹ 6247 crore. This represent the decline of -36.85% The ebitda of Dishman Carbogen Amcis Ltd for the Dec '25 is ₹ 119.77 crore as compare to the Sep '25 ebitda of ₹ 157 crore. This represent the decline of -23.71% The ebitda of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 729.88 crore as compare to the Sep '25 ebitda of ₹ 1175 crore. This represent the decline of -37.89% The net profit of Dishman Carbogen Amcis Ltd changed from ₹ -77.57 crore to ₹ -12.97 crore over 7 quarters. This represents a CAGR of -64.01% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 340.24 crore to ₹ 403.23 crore over 7 quarters. This represents a CAGR of 10.19% The Dividend Payout of Dishman Carbogen Amcis Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 4.28 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of 0.46% over 5 years .

About Dishman Carbogen Amcis Ltd

Dishman Carbogen Amcis Limited was formerly incorporated as 'Carbogen Amcis (India) Limited' on July 17, 2007.
The Company name later on, was changed to 'Dishman Carbogen Amcis Limited' on 27 March 2017.
The Company is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants.
It works manufacturing and research facilities in India, Switzerland, France, The Netherland and China. During the financial year ended 31 March 2017, Dishman Pharmaceuticals and Chemicals Limited (DPCL) and Dishman Care Limited were merged with DPCL's subsidiary Carbogen Amcis (India) Limited, with the key objective of business consolidation and simplification of the Group structure.
The name of Carbogen Amcis (India) Ltd.

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
Its branded generics business has a significant presence in markets across emerging economies including India.

FAQs for the comparison of Dishman Carbogen Amcis Ltd and Glenmark Pharmaceuticals Ltd

Which company has a larger market capitalization, Dishman Carbogen Amcis Ltd or Glenmark Pharmaceuticals Ltd?

Market cap of Dishman Carbogen Amcis Ltd is 2,927 Cr while Market cap of Glenmark Pharmaceuticals Ltd is 67,519 Cr

What are the key factors driving the stock performance of Dishman Carbogen Amcis Ltd and Glenmark Pharmaceuticals Ltd?

The stock performance of Dishman Carbogen Amcis Ltd and Glenmark Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dishman Carbogen Amcis Ltd and Glenmark Pharmaceuticals Ltd?

As of May 5, 2026, the Dishman Carbogen Amcis Ltd stock price is INR ₹186.7. On the other hand, Glenmark Pharmaceuticals Ltd stock price is INR ₹2392.6.

How do dividend payouts of Dishman Carbogen Amcis Ltd and Glenmark Pharmaceuticals Ltd compare?

To compare the dividend payouts of Dishman Carbogen Amcis Ltd and Glenmark Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.